Influenza A and BNCT03366402
Sub Populations of Immune Cells in Influenza A and B Patients
An observational study of Influenza A and B, run by Dr. Nechama Sharon at 1 site in Israel.
Trial summary
This study designed to examine changes of immune system cells sub-populations during influenza disease. Several parameters will be examined, such as: amount of sub populations, clinical parameters (body temperature and number of hospitalization days). Read more about this study
- Who is it for?
- Ages Up to 16 years
- Conditions the study is for
- Influenza A and B
- What is being tested?
- RT-PCR H1N1
- How many people
- 60 participants
- Where
- 1 siteIsrael
- Study dates
- Jan 2017to May 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 16 years
- All sexes
- No healthy volunteers
- Child
Study population: Children hospitalized at the pediatric department with signs and symptoms of flu.
Who may be able to join
- Children aged 0-16
- Have signed a written consent by parents or legal guardians
- Signs and symptoms of flu
Who cannot join
- Immune system disease
Trial locations and contacts
1 site in 1 country.
Israel1 site, 1 recruiting
- Recruiting
Sharon Nechama, Laniado Hospital
Netanya
Nechama Sharone, MD, 972-544303356, nsharon@laniado.org.il
Nechama Sharon, MD
About this study
This study designed to examine changes of immune system cells sub-populations during influenza disease. Several parameters will be examined, such as: amount of sub populations, clinical parameters (body temperature and number of hospitalization days).
The participants are children that are hospitalized in the Laniado hospital pediatric department.
Read the detailed description
Background:
In late March and early April 2009 an outbreak of a novel influenza virus designated A/H1N1 influenza (popularly known as swine flu) was reported in Mexico, with subsequent cases observed in many countries, leading to the declaration by the World Health Organization of a worldwide pandemic.
The first case of influenza A/H1N1 in Israel was diagnosed at the end of April 2009 at Laniado Hospital in a young man returning from Mexico.
Influenza A/H1N1 (Swine flu) carries a relatively high morbidity, particularly in young patients. Early identification would enable prompt initiation of therapy, thereby improving outcomes.
In 2009, during the H1N1 pandemic in Israel, a research was conducted in our department of pediatrics. The researchers Sharon et al. (1) have compared a group of 53 children infected with Influenza A H1N1, with a group of 53 children that presented with flu symptoms but were found negative for the virus. This comparison demonstrated a significant reduction in lymphocyte count during the acute phase of the disease (days 1-3) with resolution on day 7 (6-9) as well as reduction in the neutrophil count on day 5 from the onset of high fever with subsequent resolution 2-4 days later (days 7-10). This phenomenon was not observed in the patients that were not infected with the H1N1 virus. Similar results were reported by Cao and co-authors (2) that observed it in both pediatric and adult patients. Lewis at al suggested that the lymphopenia is mainly due to reduction in T cells and to a lesser extent in B cells (3). The lymphopenia typical of influenza A H3N3 during acute illness was shown to be due to a reduction in both T and B cells without alteration in the CD4:CD8 ratio. This is in contrast to the findings of Cao et al. (2) who noted an abnormal CD4:CD8 ratio in half of those who were positive for A H1N1. One of the possible explanations as proposed by Nichols and Collaborators (4) is that early lymphopenia and the later neutropenia in the influenza infected patients may represent migration of these cells from the circulation to the infected respiratory tract as a consequence of infection. Goals of our research To quantify the B, T and NK populations of lymphocytes during different stages of the disease caused by Infuenza A H1N1.
Study methods The subjects of the study were children that were hospitalized at our department with signs and symptoms of flu. The parents or legal guardians of the participants have signed a written consent. At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
Laboratory technique:
Cellular markers were assessed by flow cytometry. Cell staining was performed on single cell suspensions using pre-cooled PBS in 5 ml FACS tubes. Washing steps were performed by centrifugation for 5min, 300 g, 5°C, brake 5 after which supernatants were completely pipetted off and cell pellets (typically containing 0.2-1.0×106 cells) were re-suspended in 100 μl PBS (without Ca++and Mg++) supplemented with 0.5% bovine serum albumin, stained with specific fluorochrome-conjugated anti-human antibodies or isotype-matched non-specific controls and incubated in the refrigerator 2-8°C for 30 min. After incubation, cells were washed by centrifugation and re-suspended in 0.25-0.5 ml cold PBS.
Cells tested were stained with mouse monoclonal antibodies for CD45-FITC, CD45-PE a pan leukocyte marker, T Cell marker CD3-PE CD8-FITC, T helper cells CD4-FITC, CD8-PE, Natural killer (NK) cell marker CD56-PE, monocyte marker CD31-FITC and B cell marker CD19-PE.
Emission compensation was done by positive control tubes containing cells that were stained with CD45-FITC or CD45-PE; Dead cells were excluded by staining with 7-aminoactinomycin D, only un-stained viable cells were analyzed. At least 10,000 cellular events per sample were analyzed using the CellQuest Pro or FlowJo software. Percentages of isotype control antibody staining, not exceeding 1% stained cells, were used to set the 'positive'staining gates, and were deduced from the specific antibody results. The results are expressed as the percentage of stained cells.
- Conditions
- Influenza A and B
- Being tested
- RT-PCR H1N1
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RT-PCR H1N1Diagnostic test
At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
| Study group | Role | What they receive |
|---|---|---|
| Influenza A | Not described Receives: Diagnostic Test: RT-PCR H1N1 | |
| Influenza B | Not described Receives: Diagnostic Test: RT-PCR H1N1 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quantifing the B, T and NK populations of lymphocytes during different stages of the disease caused by Infuenza A H1N1.
The identification and quantification of the different cell types are performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
The primary outcome measure was defined as the absolute number of lymphocytes of each sub population. Thus, farther allowing us to follow both absolute numbers and relative percentage of the whole.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Dec 2017
- Study startJan 2017
- Primary completionJan 2020 (estimated)
- Study completionMay 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Influenza A and BStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dr. Nechama Sharon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Dr. Nechama Sharon, Laniado Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03366402
- Sponsor's protocol ID
- 0015-16-LND
- Status last verified
- Jan 2018
- First submitted
- 16 Nov 2017
- Last updated
- 4 Jan 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Jan 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sub Populations of Immune Cells in Influenza A and B Patients
- ClinicalTrials.gov ID
- NCT03366402
- Acronym / sponsor ID
- 0015-16-LND
- Conditions
- Influenza A and B
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Dr. Nechama SharonUniversity, hospital or other
- Study start
- Jan 2017 (actual)
- Primary completion
- Jan 2020 (estimated)
- Study completion
- May 2020 (estimated)
- First posted
- 8 Dec 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study designed to examine changes of immune system cells sub-populations during influenza disease. Several parameters will be examined, such as: amount of sub populations, clinical parameters (body temperature and number of hospitalization days).
The participants are children that are hospitalized in the Laniado hospital pediatric department.
Detailed description
Background:
In late March and early April 2009 an outbreak of a novel influenza virus designated A/H1N1 influenza (popularly known as swine flu) was reported in Mexico, with subsequent cases observed in many countries, leading to the declaration by the World Health Organization of a worldwide pandemic.
The first case of influenza A/H1N1 in Israel was diagnosed at the end of April 2009 at Laniado Hospital in a young man returning from Mexico.
Influenza A/H1N1 (Swine flu) carries a relatively high morbidity, particularly in young patients. Early identification would enable prompt initiation of therapy, thereby improving outcomes.
In 2009, during the H1N1 pandemic in Israel, a research was conducted in our department of pediatrics. The researchers Sharon et al. (1) have compared a group of 53 children infected with Influenza A H1N1, with a group of 53 children that presented with flu symptoms but were found negative for the virus. This comparison demonstrated a significant reduction in lymphocyte count during the acute phase of the disease (days 1-3) with resolution on day 7 (6-9) as well as reduction in the neutrophil count on day 5 from the onset of high fever with subsequent resolution 2-4 days later (days 7-10). This phenomenon was not observed in the patients that were not infected with the H1N1 virus. Similar results were reported by Cao and co-authors (2) that observed it in both pediatric and adult patients. Lewis at al suggested that the lymphopenia is mainly due to reduction in T cells and to a lesser extent in B cells (3). The lymphopenia typical of influenza A H3N3 during acute illness was shown to be due to a reduction in both T and B cells without alteration in the CD4:CD8 ratio. This is in contrast to the findings of Cao et al. (2) who noted an abnormal CD4:CD8 ratio in half of those who were positive for A H1N1. One of the possible explanations as proposed by Nichols and Collaborators (4) is that early lymphopenia and the later neutropenia in the influenza infected patients may represent migration of these cells from the circulation to the infected respiratory tract as a consequence of infection. Goals of our research To quantify the B, T and NK populations of lymphocytes during different stages of the disease caused by Infuenza A H1N1.
Study methods The subjects of the study were children that were hospitalized at our department with signs and symptoms of flu. The parents or legal guardians of the participants have signed a written consent. At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
Laboratory technique:
Cellular markers were assessed by flow cytometry. Cell staining was performed on single cell suspensions using pre-cooled PBS in 5 ml FACS tubes. Washing steps were performed by centrifugation for 5min, 300 g, 5°C, brake 5 after which supernatants were completely pipetted off and cell pellets (typically containing 0.2-1.0×106 cells) were re-suspended in 100 μl PBS (without Ca++and Mg++) supplemented with 0.5% bovine serum albumin, stained with specific fluorochrome-conjugated anti-human antibodies or isotype-matched non-specific controls and incubated in the refrigerator 2-8°C for 30 min. After incubation, cells were washed by centrifugation and re-suspended in 0.25-0.5 ml cold PBS.
Cells tested were stained with mouse monoclonal antibodies for CD45-FITC, CD45-PE a pan leukocyte marker, T Cell marker CD3-PE CD8-FITC, T helper cells CD4-FITC, CD8-PE, Natural killer (NK) cell marker CD56-PE, monocyte marker CD31-FITC and B cell marker CD19-PE.
Emission compensation was done by positive control tubes containing cells that were stained with CD45-FITC or CD45-PE; Dead cells were excluded by staining with 7-aminoactinomycin D, only un-stained viable cells were analyzed. At least 10,000 cellular events per sample were analyzed using the CellQuest Pro or FlowJo software. Percentages of isotype control antibody staining, not exceeding 1% stained cells, were used to set the 'positive'staining gates, and were deduced from the specific antibody results. The results are expressed as the percentage of stained cells.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Influenza A | – | Diagnostic Test: RT-PCR H1N1 |
| Influenza B | – | Diagnostic Test: RT-PCR H1N1 |
Who may qualify
- Ages
- Up to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Children hospitalized at the pediatric department with signs and symptoms of flu.
Key inclusion criteria (3 listed)
- Children aged 0-16
- Have signed a written consent by parents or legal guardians
- Signs and symptoms of flu
Key exclusion criteria (1 listed)
- Immune system disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RT-PCR H1N1At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56. | Diagnostic test | Influenza A, Influenza B |
Primary outcome
Quantifing the B, T and NK populations of lymphocytes during different stages of the disease caused by Infuenza A H1N1.
Time frame: 2 years
The identification and quantification of the different cell types are performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56. The primary outcome measure was defined as the absolute number of lymphocytes of each sub population. Thus, farther allowing us to follow both absolute numbers and relative percentage of the whole.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jan 2018.
- Individual participant dataSharing planned: No
Related trials for Influenza A and B
Not yet recruitingPhase 2/3
Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
Influenza A, Influenza B, Influenza Vaccination
Not yet recruiting
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test
SARS-CoV-2 Infection, Influenza A
RecruitingPhase 1/2
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
SARS-CoV-2, Influenza, Human
Active, not recruiting
Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses
Respiratory Tract Infections
RecruitingPhase 2
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Hematologic Malignancy, Acute Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Influenza A and B, run by Dr. Nechama Sharon at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Nechama Sharon, Dr. (+972-9-8604738, nsharon@laniado.org.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quantifing the B, T and NK populations of lymphocytes during different stages of the disease caused by Infuenza A H1N1. (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jan 2018.